About: Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer
Creator	Austin, S Byrne, S Doherty, G Fitzgerald, D Kay, E Murray, F Neilan, T Sadlier, D Scully, G
Source	PMC
abstract	BACKGROUND: Cyclooxygenase-2 (COX-2) is over-expressed in colorectal cancer (CRC), rendering tumour cells resistant to apoptosis. Selective COX-2 inhibition is effective in CRC prevention, although having adverse cardiovascular effects, thus focus has shifted to downstream pathways. METHODS: Microarray experiments identified genes regulated by COX-2 in HCA7 CRC cells. In vitro and in vivo regulation of DRAK2 (DAP kinase-related apoptosis-inducing kinase 2 or STK17β, an apoptosis-inducing kinase) by COX-2 was validated by qRT-PCR. RESULTS: Inhibition of COX-2 induced apoptosis and enhanced DRAK2 expression in HCA7 cells (4.4-fold increase at 4 h by qRT-PCR, P=0.001), an effect prevented by co-administration of PGE(2). DRAK2 levels were suppressed in a panel of human colorectal tumours (n=10) compared to normal mucosa, and showed inverse correlation with COX-2 expression (R=−0.68, R(2)=0.46, P=0.03). Administration of the selective COX-2 inhibitor rofecoxib to patients with CRC (n=5) induced DRAK2 expression in tumours (2.5-fold increase, P=0.01). In vitro silencing of DRAK2 by RNAi enhanced CRC cell survival following COX-2 inhibitor treatment. CONCLUSION: DRAK2 is a serine–threonine kinase implicated in the regulation of apoptosis and is negatively regulated by COX-2 in vitro and in vivo, suggesting a novel mechanism for the effect of COX-2 on cancer cell survival.
has issue date	2009-07-28(xsd:dateTime)
bibo:doi	10.1038/sj.bjc.6605144
bibo:pmid	19638987
has license	no-cc
sha1sum (hex)	4b4c47bbc2473d07c8ffd4d940a099e7546b9f25
schema:url	https://doi.org/10.1038/sj.bjc.6605144
resource representing a document's title	Regulation of the apoptosis-inducing kinase DRAK2 by cyclooxygenase-2 in colorectal cancer
has PubMed Central identifier	PMC2720240
has PubMed identifier	19638987
schema:publication	Br J Cancer
resource representing a document's body	covid:4b4c47bbc2473d07c8ffd4d940a099e7546b9f25#body_text
is schema:about of	named entity 'expression' named entity 'RNAi' named entity 'CRC' named entity 'patients' named entity 'Microarray' named entity 'enhanced' named entity 'COX-2 inhibitor' named entity 'survival' named entity 'threonine' named entity 'apoptosis' named entity 'REGULATION' named entity 'INDUCING' named entity 'DRAK2' named entity 'KINASE' named entity '282' named entity 'IN VIVO' named entity 'QRT-PCR' named entity 'NOVEL' named entity '0.001' named entity 'RNAI ENHANCED' named entity 'PATHWAYS' named entity 'INDUCED' named entity 'INDUCING' named entity 'PATIENTS' named entity 'DOWNSTREAM' named entity 'KINASE' named entity 'REGULATION OF APOPTOSIS' named entity '0.03' named entity 'COLORECTAL CANCER' named entity 'SUPPRESSED' named entity 'FOCUS' named entity 'PANEL' named entity 'COLORECTAL' named entity 'INVERSE' named entity 'IDENTIFIED' named entity 'MECHANISM' named entity 'MUCOSA' named entity '0.46' named entity 'TUMOURS' named entity 'APOPTOSIS' named entity 'ADMINISTRATION' named entity 'COX-2' named entity 'THREONINE' named entity 'CYCLOOXYGENASE-2' named entity 'RENDERING' named entity 'CELL SURVIVAL' named entity 'APOPTOSIS' named entity 'COLORECTAL CANCER' named entity '800' named entity 'STK17B' named entity 'IS A' named entity 'METHODS' named entity 'SERINE' named entity 'COX-2 INHIBITOR' named entity 'PREVENTION' named entity 'GENES' named entity '10%' named entity 'INHIBITOR TREATMENT' named entity 'REGULATION' named entity 'EFFECTIVE' named entity 'INHIBITION' named entity 'CONCLUSION' named entity 'HCA7' named entity 'COMPARED' named entity 'EFFECTS' named entity 'SELECTIVE COX-2 INHIBITOR' named entity 'MICROARRAY' named entity 'EXPERIMENTS' named entity 'CARDIOVASCULAR' named entity 'REGULATED' named entity 'CELLS' named entity 'ENHANCED' named entity 'CRC'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software